Breaking News Instant updates and real-time market news.

AMZN

Amazon.com

$1,527.39

-29.57 (-1.90%)

, TWX

Acquired by T

$96.23

-0.34 (-0.35%)

08:34
04/21/18
04/21
08:34
04/21/18
08:34

Trump's tweets politicize U.S. markets, Barron's says

With President Donald Trump, both politics and business appear personal as he continues his tweets aimed at individual companies, Vito Racanelli writes in this week's edition of Barron's. Before and after the election, he consistently aimed arrows at Amazon.com (AMZN) and at the proposed acquisition of Time Warner (TWX) by AT&T (T), the report noted. The President is not alone in singling out companies, Racanelli points out, adding that Democratic candidate Hillary Clinton also took issue with Mylan's (MYL) price increases for its EpiPen. Maybe it is a sign of the times, but the rise of powerful social-media platforms is the key enabling factor, the report said. Reference Link

AMZN

Amazon.com

$1,527.39

-29.57 (-1.90%)

TWX

Acquired by T

$96.23

-0.34 (-0.35%)

T

AT&T

$34.67

-0.15 (-0.43%)

MYL

Mylan

$40.73

-0.08 (-0.20%)

  • 24

    Apr

  • 25

    Apr

  • 26

    Apr

  • 27

    Apr

  • 18

    May

  • 13

    Nov

AMZN Amazon.com
$1,527.39

-29.57 (-1.90%)

04/19/18
PIPR
04/19/18
NO CHANGE
Target $1650
PIPR
Overweight
Amazon online retail segment could miss Q1 estimates, says Piper Jaffray
Piper Jaffray analyst Michael Olson says his firm's Amazon Search Index indicates Q1 online unit growth will be 21% year-over-year versus 23% in Q4, suggesting revenue that is slightly below Street expectations for the online retail segment. However, given the "strong cloud backdrop" and Piper's chief investment officer survey indicating an intent to accelerate spend, Amazon Web Services could partially offset any softness in retail, Olson tells investors in a pre-earnings research note. He also sees a high likelihood of "other" segment revenue upside in Q1 from advertising. Investors should own Amazon shares for the "plethora of topline tailwinds" and the potential for a return to margin expansion in the second half of 2018, Olson contends. He reiterates an Overweight rating on the shares with a $1,650 price target.
04/19/18
SBSH
04/19/18
NO CHANGE
Target $58
SBSH
Buy
Citi boosts eBay target to $58, raises to second top pick in Internet
eBay (EBAY) shares do not reflect the value of the recently announced new payment solution, Citi analyst Mark May tells investors in a research note. He estimates the solution will increase earnings by 20% in its first full-year and has a net present value of $8 per share. May raised his price target for eBay to $58 and $50 and elevated the stock four spots to become his second to pick in Internet, behind only Amazon.com (AMZN). He views eBay's valuation as attractive and keeps a Buy rating on the shares.
04/19/18
MSCO
04/19/18
NO CHANGE
Target $1550
MSCO
Overweight
Amazon gaining apparel market share in U.S., says Morgan Stanley
Morgan Stanley analyst Brian Nowak said his analysis shows that Amazon (AMZN) gained 1.5% of U.S. apparel market share in 2017, largely at the expense of department stores. He estimates Amazon is the second largest U.S. apparel retailer, trailing only Walmart (WMT), and expects the e-commerce giant to take the number one spot in terms of U.S. apparel market share in 2018. Cumulatively, Nowak estimates Sears (SHLD), Macy's (M) and J.C. Penney (JCP) lost 0.8% share in 2017, with shareholdings remaining roughly flat for Target (TGT) and Kohl's (KSS). He maintains an Overweight rating and $1,550 price target on Amazon shares.
04/20/18
FBCO
04/20/18
NO CHANGE
Target $1800
FBCO
Outperform
Credit Suisse sees 'steady,' 'iterative' 2018 for Amazon
Credit Suisse analyst Stephen Ju raised his price target on Amazon to $1800 from $1750 ahead of its Q1 earnings release on April 26. Ju, who has an Outperform rating on shares, told investors in a research note that Amazon is "one of the best positioned to capture the next wave of retail dollars" coming offline given its iteration track record and product innovation. Ju also said Prime Wardrobe and the connection between Whole Foods content and Prime Now distribution will serve as "spearheads" to address opportunities in apparel and groceries, which he called "large pools of dollars still left to come online."
TWX Acquired by T
$96.23

-0.34 (-0.35%)

03/19/18
JEFF
03/19/18
UPGRADE
Target $82
JEFF
Buy
Amdocs upgraded to Buy from Hold at Jefferies
Jefferies analyst Ramsey El-Assal upgraded Amdocs (DOX) to Buy and raised his price target for the shares to $82 from $70. Past mergers suggest that the AT&T (T) spend slowdown related to its acquisition of Time Warner (TWX) is only temporary, El-Assal tells investors in a research note. He believes a recovery is "on the horizon regardless of whether the merger is approved or not." The analyst sees upside to fiscal 2019 estimates for Amdocs.
04/17/18
PIVT
04/17/18
DOWNGRADE
Target $105
PIVT
Hold
Time Warner downgraded to Hold from Buy at Pivotal Research
Pivotal Research analyst Brian Wieser downgraded Time Warner (TWX) to Hold and lowered his price target for the shares to $105 from $108. The stock's value is driven by current trading levels of AT&T (T) under a presumption that the sale of the company goes through, Wieser tells investors in a research note.
04/11/18
JEFF
04/11/18
NO CHANGE
JEFF
T-Mobile, Sprint deal has more hurdles than AT&T, Time Warner, says Jefferies
A horizontal merger between T-Mobile (TMUS) and Sprint (S) poses more significant regulatory hurdles than the contested AT&T (T), Time Warner (TWX) deal does, Jefferies analyst Scott Goldman tells investors in a research note after the Wall Street Journal reported the two companies are again in merger talks. The analyst believes potential regulatory remedies could include meaningful spectrum divestitures. With that said, he thinks the combined company would create "meaningful accretion," with free cash flow per share nearly 30% higher in year three. Using multiple analysis, Goldman thinks T-Mobile shares could be worth more than $88 in a deal scenario. The stock closed yesterday up 3.4% to $63.13. Further, the analyst recommends buying the tower stocks on yesterday's selloff given his view of significant regulatory hurdles for a Sprint, T-Mobile deal. He has Buy ratings on American Tower (AMT), Crown Castle (CCI) and SBA Communications (SBAC).
03/23/18
WELS
03/23/18
NO CHANGE
Target $40
WELS
Outperform
AT&T price target lowered to $40 from $48 Wells Fargo
Wells Fargo analyst Jennifer Fritzsche lowered her price target for AT&T (T) to $40 from $48 given recent volatility and uncertainty around Time Warner (TWX) path. Nonetheless, the analyst reiterates an Outperform rating on AT&T shares and believes Q1 2018 will represent the second consecutive quarter of positive handset ads for the company.
T AT&T
$34.67

-0.15 (-0.43%)

04/12/18
OPCO
04/12/18
NO CHANGE
OPCO
T-Mobile, Sprint merger logic, still difficult to consummate, says Oppenheimer
Oppenheimer analyst Timothy Horan notes that The Wall Street Journal reported on revived preliminary merger talks after T-Mobile (TMUS)/Sprint (S) ended previous M&A discussions five months ago. The analyst believes a merger offers long-term value for both companies through better scale and synergies, but friction will center on control, relative valuation and regulatory approval concessions, which need to be agreed upon up-front. Ultimately, Horan thinks the industry will consolidate to four large companies that will all offer a quad-play service, one possibility being T-Mobile/Sprint, AT&T (T), Verizon (VZ)/Dish (DISH) and a combination of the cable companies/wireless assets.
04/12/18
NOMU
04/12/18
NO CHANGE
Target $48
NOMU
Buy
CommScope price target raised to $48 from $42 at Nomura Instinet
Nomura Instinet analyst Jeffrey Kvaal raised his price target for CommScope (COMM) to $48 saying "rapidly increasing" AT&T (T) FirstNet spending will lift the company's 2018 revenues "easily above consensus expectations." FirstNet represents a "rare inflection in a typically methodical story," Kvaal tells investors in a research note. He keeps a Buy rating on CommScope.
MYL Mylan
$40.73

-0.08 (-0.20%)

04/19/18
WELS
04/19/18
NO CHANGE
WELS
Wells says bottom has not been reached in generics pricing
After Aceto (ACET) cited the continued intense competitive and pricing pressures in the generic industry when withdrawing its guidance last night, and Novartis (NVS) this morning reported that net sales at its generic unit Sandoz dropped 4% in the quarter, Wells Fargo analyst Davis Maris says he's not ready to call the bottom in generics pricing. Those that have are premature, Maris tells investors in a research note titled "Negative Read Throughs For Generics Continue." The Aceto and Sandoz pricing news shows the data continue to be negative for U.S. generic industry pricing, the analyst contends. He sees a negative read-through for companies with large U.S. commodity generic exposure, such as Teva (TEVA) and Mylan (MYL).
04/18/18
LEHM
04/18/18
NO CHANGE
Target $230
LEHM
Overweight
Barclays sees 'significant challenges' for Botox biosimilar
Barclays analyst Douglas Tsao says that while he'd probably stop short of calling it "mission impossible," he sees "significant challenges" in the development of a biosimilar to Allergan's (AGN) Botox. Following a deep dive into the key issues Mylan (MYL) will likely face in developing a biosimilar Botox, the analyst and concluded that it seems "technically difficult and faces a long road ahead." Even a best case scenario puts timing out to 2023, Tsao tells investors in a research note. The analyst has an Overweight rating on Allergan with a $230 price target.
04/12/18
04/12/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Incyte (INCY) upgraded to Buy from Neutral at UBS with analyst Carter Gould saying the stock offers an improved risk/reward profile after resetting lower on negative epacadostat Phase 3 data and removal of the drug from analyst models. 2. TechnipFMC (FTI) upgraded to Buy from Neutral at Goldman Sachs with analyst Waqar Syed saying while his 2018/2019 EBITDA estimates are little changed, his 2020 EBITDA estimates have been raised nearly 18% owing to expectations for higher inbound orders in 2019 for the Subsea and Onshore/Offshore segments. 3. Prologis (PLD) upgraded to Buy from Hold at Jefferies with analyst Jonathan Petersen saying he sees the company posting one of the strongest levels of internal growth among the blue-chip real estate investment trusts in 2018. 4. Mylan (MYL) upgraded to Outperform from Market Perform at Leerink with analyst Ami Fadia citing valuation disconnect given the diversified business and catalyst path. 5. Summit Hotel Properties (INN) upgraded to Buy from Underperform at BofA/Merrill with analyst Shaun Kelley citing relative valuation, its potential to outperform peers on the top-line in an accelerating RevPAR environment, and lower relative cost pressure given a lower proportion of labor costs. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/12/18
JPMS
04/12/18
NO CHANGE
Target $53
JPMS
Overweight
Mylan shares remain 'highly inexpensive,' says JPMorgan
JPMorgan analyst Chris Schott says his positive longer term thesis is unchanged following Mylan's investor day. Commentary on the near-term pipeline remained upbeat and Mylan highlighted multiple long-term revenue drivers, Schott tells investors in a research note. He believes the company's "significant" generic Advair opportunity, as well as other potential near-term approvals, more than offset any downside risk from ongoing challenges in the U.S. generics market. The analyst thinks Mylan shares remain "highly inexpensive." Schott keeps an Overweight rating on the name with a $53 price target.

TODAY'S FREE FLY STORIES

15:35
09/18/18
09/18
15:35
09/18/18
15:35
Hot Stocks
Breaking Hot Stocks news story  »

CBX trading halted, news…

BIOL

Biolase

$2.06

-0.02 (-0.96%)

15:30
09/18/18
09/18
15:30
09/18/18
15:30
Conference/Events
Biolase to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

TRXC

TransEnterix

$6.04

0.24 (4.14%)

15:25
09/18/18
09/18
15:25
09/18/18
15:25
Options
TransEnterix call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 27

    Nov

MB

Mindbody

$41.15

1.1 (2.75%)

15:25
09/18/18
09/18
15:25
09/18/18
15:25
Conference/Events
Mindbody to host analyst day »

Analyst day to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
09/18/18
09/18
15:17
09/18/18
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
09/18/18
09/18
15:16
09/18/18
15:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BGS

B&G Foods

$30.40

-1.15 (-3.65%)

15:10
09/18/18
09/18
15:10
09/18/18
15:10
Options
Bearish option flow in B & G Foods as shares drop 3.8% »

Bearish option flow in B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 06

    Nov

15:10
09/18/18
09/18
15:10
09/18/18
15:10
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

YELP

Yelp

$50.19

3.905 (8.44%)

15:05
09/18/18
09/18
15:05
09/18/18
15:05
Options
Yelp call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VKTX

Viking Therapeutics

$20.35

9.95 (95.67%)

14:58
09/18/18
09/18
14:58
09/18/18
14:58
Recommendations
Viking Therapeutics analyst commentary  »

Viking price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 01

    Oct

ACHV

Achieve Life Sciences

$2.55

-0.05 (-1.92%)

14:56
09/18/18
09/18
14:56
09/18/18
14:56
Conference/Events
Achieve Life Sciences to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$362.55

12.31 (3.51%)

, VIA

Viacom

$33.80

0.05 (0.15%)

14:52
09/18/18
09/18
14:52
09/18/18
14:52
Hot Stocks
Netflix working on live-action version of 'Avatar: The Last Airbender' »

Netflix (NFLX) confirmed…

NFLX

Netflix

$362.55

12.31 (3.51%)

VIA

Viacom

$33.80

0.05 (0.15%)

VIAB

Viacom

$30.26

0.2 (0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 16

    Oct

BX

Blackstone

$37.63

0.53 (1.43%)

14:47
09/18/18
09/18
14:47
09/18/18
14:47
Conference/Events
Blackstone to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 25

    Sep

ING

ING Group

$13.00

0.05 (0.39%)

14:46
09/18/18
09/18
14:46
09/18/18
14:46
Syndicate
Breaking Syndicate news story on ING Group »

ING Group files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNST

Constellation Pharmaceuticals

$7.01

-0.64 (-8.37%)

14:44
09/18/18
09/18
14:44
09/18/18
14:44
Conference/Events
Constellation Pharmaceuticals management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 21

    Sep

NTDOY

Nintendo

$0.00

(0.00%)

14:41
09/18/18
09/18
14:41
09/18/18
14:41
Hot Stocks
Nintendo offering Fortnite bundle for Switch »

Nintendo of America…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KO

Coca-Cola

$46.06

-0.26 (-0.56%)

14:40
09/18/18
09/18
14:40
09/18/18
14:40
Hot Stocks
Coca-Cola acquires Australian maker of MOJO Kombucha, terms undisclosed »

The Coca-Cola Company has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

SPWR

SunPower

$7.43

0.85 (12.92%)

14:35
09/18/18
09/18
14:35
09/18/18
14:35
Hot Stocks
SunPower spikes higher after receiving solar tariff exclusion »

Shares of solar solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABBV

AbbVie

$93.60

-1.77 (-1.86%)

14:35
09/18/18
09/18
14:35
09/18/18
14:35
Options
AbbVie put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAIC

SAIC

$77.37

-0.58 (-0.74%)

14:30
09/18/18
09/18
14:30
09/18/18
14:30
Conference/Events
SAIC management to meet with Jefferies »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

CPA

Copa Holdings

$79.77

-0.23 (-0.29%)

14:29
09/18/18
09/18
14:29
09/18/18
14:29
Conference/Events
Copa Holdings to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABBV

AbbVie

$94.29

-1.08 (-1.13%)

14:29
09/18/18
09/18
14:29
09/18/18
14:29
Periodicals
Citron reiterates $60 AbbVie target, says lawsuit 'least of the problems' »

Citron Research just…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIPS

Vipshop

$6.06

0.07 (1.17%)

14:25
09/18/18
09/18
14:25
09/18/18
14:25
Options
Vipshop call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDEN

Golden Entertainment

$26.96

0.51 (1.93%)

14:21
09/18/18
09/18
14:21
09/18/18
14:21
Conference/Events
Golden Entertainment management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
09/18/18
09/18
14:17
09/18/18
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.